$0.03 EPS Expected for OraSure Technologies, Inc. (NASDAQ:OSUR) This Quarter


Share on StockTwits

Equities research analysts forecast that OraSure Technologies, Inc. (NASDAQ:OSUR) will report earnings of $0.03 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for OraSure Technologies’ earnings. The lowest EPS estimate is $0.01 and the highest is $0.05. OraSure Technologies reported earnings of ($0.10) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 130%. The company is expected to report its next quarterly earnings report on Wednesday, May 5th.

On average, analysts expect that OraSure Technologies will report full-year earnings of $0.65 per share for the current year, with EPS estimates ranging from $0.04 to $1.73. For the next year, analysts expect that the business will post earnings of $0.80 per share, with EPS estimates ranging from $0.08 to $2.39. Zacks’ earnings per share averages are an average based on a survey of research analysts that cover OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Monday, March 1st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.04). OraSure Technologies had a negative return on equity of 3.51% and a negative net margin of 9.05%. The firm had revenue of $62.90 million for the quarter, compared to analysts’ expectations of $57.30 million. During the same quarter in the previous year, the firm posted $0.04 EPS. The firm’s revenue for the quarter was up 26.6% compared to the same quarter last year.

A number of brokerages have recently issued reports on OSUR. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 3rd. Citigroup reduced their price target on OraSure Technologies from $18.00 to $16.00 in a research report on Tuesday, March 2nd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. OraSure Technologies has an average rating of “Buy” and a consensus price target of $16.71.

A number of institutional investors have recently added to or reduced their stakes in OSUR. Camber Capital Management LP acquired a new position in OraSure Technologies during the 3rd quarter worth approximately $33,468,000. Deerfield Management Company L.P. Series C acquired a new position in shares of OraSure Technologies in the 3rd quarter valued at approximately $26,299,000. BlackRock Inc. raised its position in shares of OraSure Technologies by 1.9% in the 4th quarter. BlackRock Inc. now owns 11,031,726 shares of the medical instruments supplier’s stock valued at $116,772,000 after purchasing an additional 203,155 shares in the last quarter. Norges Bank acquired a new position in shares of OraSure Technologies in the 4th quarter valued at approximately $2,063,000. Finally, Earnest Partners LLC raised its position in shares of OraSure Technologies by 24.9% in the 3rd quarter. Earnest Partners LLC now owns 890,587 shares of the medical instruments supplier’s stock valued at $10,838,000 after purchasing an additional 177,722 shares in the last quarter. 98.13% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:OSUR traded down $0.13 during trading on Friday, reaching $10.32. 4,059 shares of the stock were exchanged, compared to its average volume of 1,126,327. OraSure Technologies has a 12-month low of $9.46 and a 12-month high of $19.75. The firm has a market cap of $742.48 million, a price-to-earnings ratio of -45.43 and a beta of 0.04. The firm’s 50-day moving average price is $11.11 and its 200 day moving average price is $12.57.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Further Reading: What is the Producer Price Index (PPI)?

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.